Charles river unveils lentivation platform to expedite lvv-based gene therapy manufacturing

Wilmington, mass.--(business wire)--charles river laboratories international, inc. (nyse: crl) today announced the launch of its lentiviral vector (lvv) manufacturing platform, lentivation™. the platform has the capability to reduce lvv manufacturing timelines for gene and gene-modified cell therapies by up to 60 percent, translating to fewer than seven months compared to traditional manufacturing workflows. charles river provides viral vector production services ranging from clone construction.
CRL Ratings Summary
CRL Quant Ranking